Document ID: chunk:federal_register_of_legislation:F2021L01169:reg:9:p3
Version: federal_register_of_legislation:F2021L01169
Segment Type: reg
Provision Reference: reg 9 (pt 3/3)
Character Range: 8997–11166

of carpal tunnel syndrome;
Note: chronic renal failure is defined in the Schedule 1 - Dictionary.
(23)      having acromegaly before the clinical worsening of carpal tunnel syndrome;
Note: acromegaly is defined in the Schedule 1 - Dictionary.
(24)      having gout involving the affected wrist or hand at the time of the clinical worsening of carpal tunnel syndrome;
(25)      having a space-occupying lesion in the affected carpal tunnel at the time of the clinical worsening of carpal tunnel syndrome;
            Note: Examples of a space-occupying lesion include neoplasm, ganglion, tenosynovitis and muscle intrusion.
(26)      having haemorrhage involving the affected carpal tunnel at the time of the clinical worsening of carpal tunnel syndrome;
            Note: Examples of situations in which haemorrhage involving the affected carpal tunnel may occur include haemophilia, von Willebrand's disease and taking anticoagulants.
(27)       having infection involving the affected carpal tunnel at the time of the clinical worsening of carpal tunnel syndrome;
            Note: Examples of infections that may involve the carpal tunnel include histoplasmosis, tuberculosis and chikungunya fever.
(28)      having osteoarthritis or inflammatory arthritis involving the affected wrist or hand at the time of the clinical worsening of carpal tunnel syndrome;
Note: inflammatory arthritis is defined in the Schedule 1 - Dictionary.
(29)      having diabetes mellitus at the time of the clinical worsening of carpal tunnel syndrome;
(30)      taking an aromatase inhibitor within the 2 years before the clinical worsening of carpal tunnel syndrome;
Note: Examples of aromatase inhibitors include anastrozole, exemestane and letrozole.
(31)      taking an immune checkpoint inhibitor within the 2 years before the clinical worsening of carpal tunnel syndrome;
            Note: Examples of immune checkpoint inhibitors include pembrolizumab, nivolumab, ipilimumab and avelumab.
(32)      being pregnant within the 3 months before the clinical worsening of carpal tunnel syndrome;
(33)      inability to obtain appropriate clinical management for carpal tunnel syndrome.